These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16427862)

  • 1. Effect of aprotinin and recombinant variants on platelet protease-activated receptor 1 activation.
    Day JR; Haskard DO; Taylor KM; Landis RC
    Ann Thorac Surg; 2006 Feb; 81(2):619-24. PubMed ID: 16427862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1.
    Poullis M; Manning R; Laffan M; Haskard DO; Taylor KM; Landis RC
    J Thorac Cardiovasc Surg; 2000 Aug; 120(2):370-8. PubMed ID: 10917956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery.
    Day JR; Punjabi PP; Randi AM; Haskard DO; Landis RC; Taylor KM
    Circulation; 2004 Oct; 110(17):2597-600. PubMed ID: 15262827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aprotinin and the protease-activated receptor 1 thrombin receptor: antithrombosis, inflammation, and stroke reduction.
    Day JR; Landis RC; Taylor KM
    Semin Cardiothorac Vasc Anesth; 2006 Jun; 10(2):132-42. PubMed ID: 16959740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1.
    Day JR; Taylor KM; Lidington EA; Mason JC; Haskard DO; Randi AM; Landis RC
    J Thorac Cardiovasc Surg; 2006 Jan; 131(1):21-7. PubMed ID: 16399290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
    Wu CC; Teng CM
    Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
    Bilodeau ML; Hamm HE
    J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PAR4 signaling mediates ethanol-induced attenuation of platelet function in vitro.
    Kasuda S; Sakurai Y; Shima M; Morimura Y; Kudo R; Takeda T; Ishitani A; Yoshioka A; Hatake K
    Alcohol Clin Exp Res; 2006 Sep; 30(9):1608-14. PubMed ID: 16930224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.
    Nieman MT; Warnock M; Hasan AA; Mahdi F; Lucchesi BR; Brown NJ; Murphey LJ; Schmaier AH
    J Pharmacol Exp Ther; 2004 Nov; 311(2):492-501. PubMed ID: 15210836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invited commentary.
    Rinder HM
    Ann Thorac Surg; 2006 Feb; 81(2):624. PubMed ID: 16427863
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
    Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
    Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis.
    Khan TA; Bianchi C; Voisine P; Sandmeyer J; Feng J; Sellke FW
    Ann Thorac Surg; 2005 May; 79(5):1545-50. PubMed ID: 15854931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of plasmin-induced platelet aggregation.
    Watabe A; Ohta M; Matsuyama N; Mizuno K; el Borai N; Tanimoto T; Kawanishi T; Hayakawa T
    Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):341-52. PubMed ID: 9261893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
    Tanaka KA; Szlam F; Levy JH
    Br J Haematol; 2006 Jul; 134(1):77-82. PubMed ID: 16803571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of novel peptide inhibitors of thrombin-induced platelet activation.
    Burke FM; Warnock M; Schmaier AH; Mosberg HI
    Chem Biol Drug Des; 2006 Nov; 68(5):235-8. PubMed ID: 17177882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
    Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
    Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets.
    Cumashi A; Ansuini H; Celli N; De Blasi A; O'Brien PJ; Brass LF; Molino M
    Thromb Haemost; 2001 Mar; 85(3):533-8. PubMed ID: 11307827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
    Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
    Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protease activated receptors: clinical relevance to hemostasis and inflammation.
    Landis RC
    Hematol Oncol Clin North Am; 2007 Feb; 21(1):103-13. PubMed ID: 17258121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease-activated receptor 4 uses anionic residues to interact with alpha-thrombin in the absence or presence of protease-activated receptor 1.
    Nieman MT
    Biochemistry; 2008 Dec; 47(50):13279-86. PubMed ID: 19053259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.